INTRODUCTION
Streptomycin was the first effective antibiotic for the therapy of tularemia, and remains the drug of choice (1, 14, 21) . Alternatives are needed, however, because of (i) the possibility of infection by streptomycin-resistant Francisella tularensis (11) , (ii) the need for injection of streptomycin with the attendant inconvenience and discomfort, and (iii) the toxicity of streptomycin. Of the many other antibiotics active against F. tularensis, the best evaluated and most frequently used are the tetracyclines and chloramphenicol (2, 9, 11, 12, 20) . (Because chloramphenicol offers no advantages over the tetracyclines in the treatment of tularemia and has significant toxicity, only the tetracyclines will be considered hereafter except in reviewing earlier work.) Patients with acute tularemia respond well to therapy with either streptomycin or tetracycline; symptoms rapidly remit, and defervescence is prompt (Fig. 1) . The late consequences of treatment with the two antibiotics differ, however. Relapses rarely follow exhibition of reasonable doses of streptomycin but occur frequently after therapy with conventional regimens of tetracycline (2, 11) . Such relapses result from the persistence of bacteria in the tissues, not the emergence of tetracyclineresistant organisms; retreatment with tetracycline is effective (Fig. 1) .
In addition to their use in the management of tularemia, antibiotics may be employed for prophylaxis, used here to mean treatment instituted during the incubation period to prevent illness. Results have been similar to those 1 Present address: Department of Microbiology, The Johns Hopkins University School of Medicine, Baltimore, Md. achieved in the therapy of acute disease: streptomycin prevents illness, but broad-spectrum drugs merely delay disease. McCrumb et al. (9) , for example, consistently protected volunteers by administration of streptomycin for 5 days after intradermal inoculation with F. tularensis, whereas only two of five volunteers were protected from tulalemia by 5 days of prophylactic treatment with chloramphenicol.
Comparison of their actions against F. tularensis in vitro may help to explain the difference in effectiveness of streptomycin and tetracycline in both the prophylaxis and therapy of tularemia. Streptomycin is bactericidal in vitro, and may eradicate the organisms without the intervention of host mechanisms. Tetracycline, even in high concentration, merely suppresses multiplication; organisms persist in the tissues until destroyed by host defenses. F. tularensis, like other intracellular pathogens (5, 17) , is cleared from the cells slowly even when multiplication is prevented, e.g., by a bacteriostatic antibiotic. The relative inefficiency of host defense against F. tularensis is a crucial factor in determining the effectiveness of prophylaxis and therapy of tularemia with bacteriostatic agents. In the Conference on Airborne Infection held in 1960, McCrumb cited the imperfect results achieved with bacteriostatic drugs and suggested that either prolonged or intermittent treatment might be required if they were to be completely effective (10) . The success of such regimens in other intracellular infections, e.g., scrub typhus (8, 16) and Q fever (18, 19) , prompted the present studies of tetracycline prophylaxis and therapy of experimental airborne tularemia in Macaca mulatta and man. The failure of prolonged tetracycline prophylsix untreated monkeys died of tularemia, laxis to prevent simian airborne tularemia results vo of those in the several prophylaxis from the limited defenses of M. mulatta against expired within 70 days of exposure, the F tularensis. Although man is quite susceptible n of observation (Table 1) .
to infection with airborne F. tularensis, he has ise the timing of the institution of treat-better defense mechanisms than M. mulatta; e.g., ay have important bearing on the effective-the human respiratory infectious dose is about prophylaxis of intracellular infection three times that of monkeys (15) , and untreated tracycline prophylaxis of Q fever merely airborne tularemia has a mortality of less than 50% in man (13) but is usually fatal in monkeys.
It seemed likely, therefore, that prophylactic regimens of tetracycline which were only partially successful in monkeys might succeed in man.
The results of trials in volunteers who inhaled 25,000 F. tularensis SCHU-S4 confirmed the prediction (Table 3 The initial objective in the therapy of acute tularemia is the rapid relief of clinical manifestations, an objective readily accomplished with bacteriostatic drugs (see above). Thereafter, the problem is the same as that in prophylaxis-the suppression of multiplication for sufficient time for host mechanisms to eradicate the microorganisms. The major difference, then, in the two situations is the extent of microbial multiplication, and supposedly the degree of stimulation of defense mechanisms, prior to initiation of treatment. Therefore, after control of clinical illness, therapeutic regimens similar to those found effective in prophylaxis should result in a negligible relapse rate, even if therapy is instituted early in the course of disease.
Volunteers exposed to 25,000 airborne F. tularensis (see above) became acutely ill after a mean incubation period of 3 days (range of 2 to 7 days). The onset of illness was gradual in 15 % of subjects, and a biphasic course was occasionally observed. Treatment was instituted early, within 48 hr of initial signs of illness in 85 % of the men, and in no case later than the 5th day after initial signs. Large doses of tetracycline were administered during the first 24 hr, i.e. 1 g every 6 hr, to insure high initial blood levels, and the daily maintenance quantity was administered thereafter in four equal doses.
During the initial phases of evaluation of tetracycline therapy, intermittent treatment schedules were examined. Therapy consisting of three five-day courses of tetracycline (0.5 g every 6 hr) separated by 3 days without drug was efficacious (Fig. 4) ; the patients responded rapidly and remained well thereafter. These results led to an attempt to reduce the number of treatment periods. After the initial 5 days of therapy, no additional drug was given to another group of volunteers until ordered by the ward physician, who was instructed to institute treatment at the first sign, no matter how equivocal, of a recurrence. The results were unsatisfactory (Fig. 5) . In most instances, the recurrences were so rapid in onset that the men were disabled by the time treatment was effectively instituted; i.e., the time between recognition of possible recurrence and achievement of effective levels of drug in the patient exceeded the time required for the illness to progress from well-being to disability. Moreover, three courses of treatment were administered in 6 of the 8 subjects. It seemed, therefore, that there was little likelihood of developing effective interrupted treatment schedules either employing substantially less drug or of shorter duration than that originally evaluated. Later studies (see below) indicated that continuous tetracycline therapy with similar quantities of drug was equally effective; interrupted therapy, therefore, did not offer any advantage over the simpler continuous treatment schedule.
Prompt clinical improvement was achieved with the continuous therapeutic regimens listed in Table 4 . Treatment with 22 g of tetracycline in 10 days resulted in a high incidence of relapse. The same daily dose continued through 15 days was not, however, followed by relapse in any ofthe 20 patients, 12 infected with the SCHU-S4 strain and 8 infected with the SCHU-S5 strain. The SCHU-S5 strain differs from SCHU-S4 strain only in resistance to streptomycin, SCHU-S5 resisting more than 1,000 Ag/ml. When the daily dose was halved, two of eight men had a relapse after 15 days of therapy.
As predicted, the simplest and most successful tetracycline regimen for prophylaxis was very similar to the best therapeutic regimen, i.e., 1 g of tetracycline twice daily for 14 days compared with 4 g of tetracycline the 1st day followed by 0.5 g four times daily for 14 additional days. From a practical standpoint, it would be desirable to have a single schedule of tetracycline administration for both prophylaxis and therapy of airborne tularemia. Therefore, six volunteei s with acute illness were treated exactly according to the schedule found successful for prophylaxis; all recovered rapidly and remained well. Thus, a simple schedule of tetracycline treatment was effective in both prophylaxis and therapy of human aiiborne tularemia; that schedule was 1 g of tetracycline twice daily for 14 days. Because this treatment schedule was suitable for infections induced by exposure to a large number of organisms, the regimen should be satisfactory over the entire range of exposure encountered either in nature or in laboratory accident.
OrHER ANTmIoIcs For infection with streptomycin-sensitive F. tularensis, the clinician has a choice of effective antibiotics, particularly streptomycin and tetracycline. In cases of infection by streptomycinresistant organisms, effective alternatives to tetracycline are needed. Therefore, a number of antibiotics active against F. tularensis SCHU-S5 (streptomycin-resistant) in vitro have been evaluated in the therapy of airborne infection of monkeys with the SCHU-S5 strain ( Table 5 ). The inhaled dose was 10,000 organisms; 12 control monkeys became ill within 72 hr and died between the 7th and 15th day after exposure. Therapy was started early, i.e., after 12 hr with a Divided into three doses. Therapy was continued for 7 days or until the animal was afebrile for 72 hr, whichever was longer.
b An animal was classified as having a slow response if more than 72 hr of treatment were required before it became afebrile. temperature >40 C or a single temperature of 41 C or greater. Tetracycline treatment resulted in rapid response, but, as expected, relapses followed this short couise (see Table 5 ). Kanamycin, which was bactericidal in vitro, was bactericidal in vivo as well, and effected cure, albeit the initial response was somewhat slow in two monkeys. Novobiocin (Eigelsbach, Herring, and Halstead, Bacteriol. Proc., p. 69, 1957) gave results similar to those obtained with tetracycline. Although gentamicin was quite active against F. tularensis SCHU-S5 in vitro, therapy with it was disappointing. All monkeys responded, but only slowly; three of the eight had a relapse.
These results suggest that novobiocin may be employed in the therapy of human tularemia, but that prolonged courses, such as those found necessary with other bacteriostatic drugs, are likely to be necessary if therapy is to be completely successful. Although the bactericidal drug kanamycin was highly effective, its toxicity is such that it cannot be recommended for primary treatment The elegant work of Dr. Sawyer and his colleagues presents data which are of considerable importance, not only to those dealing with tularemia and related diseases, but also to many investigators who are interested in the general principles of antibiotic therapy and prophylaxis. This discussion is based on a general perspective, with emphasis on the prophylactic aspects.
All chemotherapeutic activity must be viewed in terms of the therapeutic ratio concept. Since there is rarely an assurance in natural situations that any given individual upon exposure will develop a clinical illness, the therapeutic ratio in the prophylactic situation has to be expressed in terms of group risk, group results, and group toxicity. Thus, if only one-half of an exposed population is destined to become ill and the prophylactic regimen gives no better end results than the treatment of half the group of subjects who actually become ill, the toxicity is doubled for the group as a whole and the results are no better than those of therapy; hence, the therapeutic ratio is less favorable. Since the accentuation of toxicity is the most marked effect of prophylaxis, prophylaxis is usually attempted with the least toxic drugs or with a reduced dose. In addition, because it is often not possible to determine with accuracy the expected infection rate in the natural situation, it has been more difficult to measure prophylactic than therapeutic benefits. Clearly, the animal and volunteer studies of Sawyer meet the problem of evaluation well and thus provide important insight. Unfortunately, even the results of treatment of a random sample of an exposed population in a semiclosed situation, when the infection rate is unpredictable, may be difficult to interpret, since the treatment of some members of the group may influence the infection rate among the untreated.
The most important principle illustrated by these data is the primary importance of the host defense mechanisms. The 
